Repros Therapeutics Stock Rating Upgraded by Zacks (RPRX)
Repros Therapeutics (NASDAQ:RPRX) was upgraded by Zacks from a “neutral” rating to an “outperform” rating in a research note issued on Monday, Analyst Ratings News reports. The firm currently has a $23.50 price objective on the stock. Zacks‘ price objective points to a potential upside of 9.00% from the company’s current price.
Repros Therapeutics (NASDAQ:RPRX) traded up 0.37% during mid-day trading on Monday, hitting $21.56. The stock had a trading volume of 297,194 shares. Repros Therapeutics has a 1-year low of $8.42 and a 1-year high of $29.79. The stock has a 50-day moving average of $18.53 and a 200-day moving average of $20.17. The company’s market cap is $496.1 million.
A number of other analysts have also recently weighed in on RPRX. Analysts at Piper Jaffray initiated coverage on shares of Repros Therapeutics in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $26.00 price target on the stock. Analysts at Ascendiant Capital Markets downgraded shares of Repros Therapeutics from a “strong-buy” rating to a “buy” rating in a research note to investors on Wednesday, October 23rd. They now have a $25.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average target price of $29.50.
Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.